These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15758648)

  • 21. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis.
    Zafra C; Abraldes JG; Turnes J; Berzigotti A; Fernández M; Garca-Pagán JC; Rodés J; Bosch J
    Gastroenterology; 2004 Mar; 126(3):749-55. PubMed ID: 14988829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complications of cirrhosis. I. Portal hypertension.
    Bosch J; García-Pagán JC
    J Hepatol; 2000; 32(1 Suppl):141-56. PubMed ID: 10728801
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.
    Abraldes JG; Albillos A; Bañares R; Turnes J; González R; García-Pagán JC; Bosch J
    Gastroenterology; 2009 May; 136(5):1651-8. PubMed ID: 19208350
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Decreasing hepatic vascular tone by liver-specific NO donors: wishful thinking or a promising reality?
    Bosch J
    J Hepatol; 2003 Dec; 39(6):1072-5. PubMed ID: 14642629
    [No Abstract]   [Full Text] [Related]  

  • 25. Variceal bleeding: pharmacological therapy.
    Bosch J; Abraldes JG
    Dig Dis; 2005; 23(1):18-29. PubMed ID: 15920322
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Leptin receptor blockade reduces intrahepatic vascular resistance and portal pressure in an experimental model of rat liver cirrhosis.
    Delgado MG; Gracia-Sancho J; Marrone G; Rodríguez-Vilarrupla A; Deulofeu R; Abraldes JG; Bosch J; García-Pagán JC
    Am J Physiol Gastrointest Liver Physiol; 2013 Oct; 305(7):G496-502. PubMed ID: 23886859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The protection of myocardial ischemia--reperfusion injury].
    Miura M; Fujiwara Y
    Nihon Rinsho; 2003 Apr; 61 Suppl 4():667-74. PubMed ID: 12735048
    [No Abstract]   [Full Text] [Related]  

  • 28. Continuous prazosin administration in cirrhotic patients: effects on portal hemodynamics and on liver and renal function.
    Albillos A; Lledó JL; Rossi I; Pérez-Páramo M; Tabuenca MJ; Bañares R; Iborra J; Garrido A; Escartín P; Bosch J
    Gastroenterology; 1995 Oct; 109(4):1257-65. PubMed ID: 7557093
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Role of endothelial nitric oxide synthase in the development of portal hypertension in the carbon tetrachloride-induced liver fibrosis model.
    Theodorakis NG; Wang YN; Wu JM; Maluccio MA; Sitzmann JV; Skill NJ
    Am J Physiol Gastrointest Liver Physiol; 2009 Oct; 297(4):G792-9. PubMed ID: 19628654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tempol administration, a superoxide dismutase mimetic, reduces hepatic vascular resistance and portal pressure in cirrhotic rats.
    García-Calderó H; Rodríguez-Vilarrupla A; Gracia-Sancho J; Diví M; Laviña B; Bosch J; García-Pagán JC
    J Hepatol; 2011 Apr; 54(4):660-5. PubMed ID: 21159403
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nitric oxide and portal hypertension: interface of vasoreactivity and angiogenesis.
    Langer DA; Shah VH
    J Hepatol; 2006 Jan; 44(1):209-16. PubMed ID: 16297493
    [No Abstract]   [Full Text] [Related]  

  • 32. Pharmacologic treatment of portal hypertension.
    Rodríguez-Pérez F; Groszmann RJ
    Gastroenterol Clin North Am; 1992 Mar; 21(1):15-40. PubMed ID: 1349005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A liver-specific nitric oxide donor improves the intra-hepatic vascular response to both portal blood flow increase and methoxamine in cirrhotic rats.
    Loureiro-Silva MR; Cadelina GW; Iwakiri Y; Groszmann RJ
    J Hepatol; 2003 Dec; 39(6):940-6. PubMed ID: 14642609
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacological treatment of portal hypertension.
    González-Abraldes J; Bosch J; García-Pagán JC
    Curr Opin Investig Drugs; 2001 Oct; 2(10):1407-13. PubMed ID: 11890356
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nitric oxide and portal hypertension: its role in the regulation of intrahepatic and splanchnic vascular resistance.
    Wiest R; Groszmann RJ
    Semin Liver Dis; 1999; 19(4):411-26. PubMed ID: 10643626
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intraportal administration of glyceryl trinitrate or nitroprusside exerts more systemic than intrahepatic effects in anaesthetised cirrhotic rats.
    Van de Casteele M; Hösli M; Sägesser H; Reichen J
    J Hepatol; 1999 Aug; 31(2):300-5. PubMed ID: 10453944
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options.
    Grace JA; Herath CB; Mak KY; Burrell LM; Angus PW
    Clin Sci (Lond); 2012 Aug; 123(4):225-39. PubMed ID: 22548407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current concepts on the pathophysiology of portal hypertension.
    Rodríguez-Vilarrupla A; Fernández M; Bosch J; García-Pagán JC
    Ann Hepatol; 2007; 6(1):28-36. PubMed ID: 17297426
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vascular Targets for the Treatment of Portal Hypertension.
    Brusilovskaya K; Königshofer P; Schwabl P; Reiberger T
    Semin Liver Dis; 2019 Nov; 39(4):483-501. PubMed ID: 31315135
    [TBL] [Abstract][Full Text] [Related]  

  • 40. NCX-1000, a nitric oxide-releasing derivative of ursodeoxycholic acid, ameliorates portal hypertension and lowers norepinephrine-induced intrahepatic resistance in the isolated and perfused rat liver.
    Fiorucci S; Antonelli E; Brancaleone V; Sanpaolo L; Orlandi S; Distrutti E; Acuto G; Clerici C; Baldoni M; Del Soldato P; Morelli A
    J Hepatol; 2003 Dec; 39(6):932-9. PubMed ID: 14642608
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.